AGC Biologics Breaks Ground on New Multipurpose Facility in Denmark

Published on: 

AGC Biologics has broken ground on a new multipurpose facility in Copenhagen, Denmark, that will increase capacity.

AGC Biologics has broken ground at its Cophenhagen, Denmark, site for a new multipurpose facility that will expand the company’s capacity and space to accommodate new and existing projects, AGC Biologics announced on Aug. 20, 2021.

The new facility will include a manufacturing building, an office building, and a visitor center. The four-story manufacturing building will consist of approximately 8000 m2 distributed across manufacturing, quality control laboratories, technical, and warehouse areas. Manufacturing will be based on genetically modified organisms with a biosafety level 1 status manufactured with single-use technology in clean rooms. The expansion will more than double AGC Biologics’ single-use bioreactor mammalian cell-culture capacity in Copenhagen and is expected to generate around 250–300 new job positions in Denmark.

“We are excited to announce the groundbreaking of the new facility,” said AGC Biologics’ CEO Patricio Massera, in a company press release. “We are fully committed to understand and meet our customers’ needs, as we continuously seek to provide new capacity and new services.”


“We are now establishing a new state-of-the-art facility with a flexible and efficient set-up for biologic drug substance manufacturing,” said Copenhagen site head, Andrea C. Porchia, in the press release. “It will be a great facility, and we are looking forward to making it available for existing and new customers.”

Source: AGC Biologics